Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

Kumi Oshima, Miki Sato, Shinya Okuda, Kiriko Terasako, Hideki Nakasone, Shinichi Kako, Rie Yamazaki, Yukie Tanaka, Aki Tanihara, Takakazu Higuchi, Junji Nishida, Ikuo Nakamura, Yukio Yoshida, Yoshinobu Kanda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The appearance of hepatitis B surface antigen (HBsAg) in patients previously positive for antibody to this antigen (HBsAb) is called reverse seroconversion, a rare complication after hematopoietic stem cell transplantation (HSCT), which occurs almost exclusively after HSCT from an HBsAb-negative donor and the development of chronic graft-versus-host disease (CGVHD). However, we experienced a patient who developed reverse seroconversion 23 months after unrelated HSCT even in the absence of immunosuppressants use or CGVHD. Serum immunoglobulin level was persistently normal. Therefore, all HBsAb-positive recipients should be considered to be at risk for HBV reactivation, even in patients without any risk factors.

Original languageEnglish
Pages (from-to)73-75
Number of pages3
JournalHematology
Volume14
Issue number2
DOIs
Publication statusPublished - 2009 Jun 17

    Fingerprint

Keywords

  • Graft-versus-host disease
  • Hematopoietic stem cell transplantation
  • Hepatitis B virus
  • Reverse seroconversion

ASJC Scopus subject areas

  • Hematology

Cite this

Oshima, K., Sato, M., Okuda, S., Terasako, K., Nakasone, H., Kako, S., Yamazaki, R., Tanaka, Y., Tanihara, A., Higuchi, T., Nishida, J., Nakamura, I., Yoshida, Y., & Kanda, Y. (2009). Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. Hematology, 14(2), 73-75. https://doi.org/10.1179/102453309X385223